Esophageal cancer screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
In 1983, a study was carried out in Hishun village, China. Due to different dietary factors, the incidence of esophageal cancer amongst these people was particularly high. | *In 1983, a study was carried out in Hishun village, China. | ||
6758 subjects were examined by esophageal exfoliative cytology, 1729 had marked dysplasia and 2411 had mild dysplasia of esophageal epithelium. Those with marked dysplasia were randomly divided into 3 groups and given: antitumor B (Chinese herbs); retinamide (4-Ethoxycarbophenylretinamide) and placebo. The subjects with mild dysplasia were randomly divided into 2 groups for treatment with riboflavin and placebo. They took their respective treatments for 3 years and were then reexamined using cytology. The incidence of esophageal cancer in the antitumor B group was reduced by 53% as compared with that of the placebo group (8.3%). The incidence of esophageal cancer in retinamide and riboflavin groups were reduced by 33.7% and 19% as compared with those of the control groups. | *Due to different dietary factors, the incidence of esophageal cancer amongst these people was particularly high. | ||
*6758 subjects were examined by esophageal exfoliative cytology, 1729 had marked dysplasia and 2411 had mild dysplasia of esophageal epithelium. | |||
*Those with marked dysplasia were randomly divided into 3 groups and given: antitumor B (Chinese herbs); retinamide (4-Ethoxycarbophenylretinamide) and placebo. | |||
*The subjects with mild dysplasia were randomly divided into 2 groups for treatment with riboflavin and placebo. | |||
*They took their respective treatments for 3 years and were then reexamined using cytology. | |||
*The incidence of esophageal cancer in the antitumor B group was reduced by 53% as compared with that of the placebo group (8.3%). | |||
*The incidence of esophageal cancer in retinamide and riboflavin groups were reduced by 33.7% and 19% as compared with those of the control groups. | |||
*These results demonstrated that the secondary prevention of esophageal cancer is effective in the prevention of esophageal cancer.<ref name="pmid3219974">{{cite journal |vauthors=Lin PZ, Zhang JS, Cao SG, Rong ZP, Gao RQ, Han R, Shu SP |title=[Secondary prevention of esophageal cancer--intervention on precancerous lesions of the esophagus] |language=Chinese |journal=Zhonghua Zhong Liu Za Zhi |volume=10 |issue=3 |pages=161–6 |year=1988 |pmid=3219974 |doi= |url=}}</ref> | |||
==References== | ==References== | ||
| Line 23: | Line 30: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
* | |||
Revision as of 15:20, 11 December 2017
|
Esophageal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Esophageal cancer screening On the Web |
|
American Roentgen Ray Society Images of Esophageal cancer screening |
|
Risk calculators and risk factors for Esophageal cancer screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]
Overview
Secondary prevention may be effective in reducing the incidence of esophageal cancer, if treated early at the dysplasia stage with monoclonal antibody therapy.
Secondary Prevention
- In 1983, a study was carried out in Hishun village, China.
- Due to different dietary factors, the incidence of esophageal cancer amongst these people was particularly high.
- 6758 subjects were examined by esophageal exfoliative cytology, 1729 had marked dysplasia and 2411 had mild dysplasia of esophageal epithelium.
- Those with marked dysplasia were randomly divided into 3 groups and given: antitumor B (Chinese herbs); retinamide (4-Ethoxycarbophenylretinamide) and placebo.
- The subjects with mild dysplasia were randomly divided into 2 groups for treatment with riboflavin and placebo.
- They took their respective treatments for 3 years and were then reexamined using cytology.
- The incidence of esophageal cancer in the antitumor B group was reduced by 53% as compared with that of the placebo group (8.3%).
- The incidence of esophageal cancer in retinamide and riboflavin groups were reduced by 33.7% and 19% as compared with those of the control groups.
- These results demonstrated that the secondary prevention of esophageal cancer is effective in the prevention of esophageal cancer.[1]